The FDA has approved intranasal etripamil (Cardamyst; Milestone Pharmaceuticals) for the acute treatment of paroxysmal supraventricular tachycardia (PSVT), making it the first self-administered, ...
The U.S. Food and Drug Administration has announced a nationwide recall of nasal spray, which officials report has been found ...
Milestone Pharmaceuticals announced the FDA approval of prescription etripamil nasal spray for the treatment of acute ...
Milestone Pharmaceuticals Inc.’s CARDAMYST nasal spray wins FDA approval for PSVT, but faces tough competition and market ...
ReBoost Nasal Spray was recalled after it was "found to contain yeast/mold and microbial contamination," the FDA states, adding, "There is a reasonable probability that adverse health consequences, ...
The FDA approved etripamil (Cardamyst) nasal spray for at-home treatment of paroxysmal supraventricular tachycardia (PSVT), ...
Respiratory viruses that have diverse strains and mutate rapidly, such as influenza and COVID-19, are difficult to block ...
The self-administered treatment rapidly converts patients into sinus rhythm and may reduce trips to the hospital.
The spray was distributed nationwide, according to the recall notice.
5d
Nasal spray sold nationwide recalled due to mold, ‘life-threatening' infections possible, FDA says
The voluntary recall of ReBoost Nasal Spray was issued Wednesday by MediNatura New Mexico, according to an announcement from ...
Oxytocin is a peptide hormone involved in social bonding, reproduction, and childbirth. Defects in oxytocin biology have been implicated in neurodegenerative disorders ranging from frontotemporal ...
The MarketWatch News Department was not involved in the creation of this content.-- Phase 3 CDKL5 deficiency disorder (CDD) results: UCB shares 21 scientific abstracts, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback